Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 51 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Oxybutynin Chloride Clear all
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition

NCT00224016
View directory record Official record
Conditions
Detrusor Hyperreflexia
Interventions
Oxybutynin
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
6 Years to 15 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
23
States / cities
Little Rock, Arkansas • Orange County, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Results available

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

NCT01557244
View directory record Official record
Conditions
Urinary Bladder, Neurogenic
Interventions
Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin, Fesoterodine PR, Fesoterodine BIC 2 mg, Fesoterodine BIC 4 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
18
States / cities
Tucson, Arizona • Orange, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products

NCT03205605
View directory record Official record
Conditions
Heat Effect
Interventions
oxybutynin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

NCT00224029
View directory record Official record
Conditions
Detrusor Hyperreflexia
Interventions
Oxybutynin transdermal system
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
6
States / cities
Atlanta, Georgia • The Bronx, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2010 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Not applicable Interventional

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

NCT00892450
View directory record Official record
Conditions
Parkinson's Disease, Overactive Bladder
Interventions
Oxybutynin and darifenacin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 4 Interventional Results available

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

NCT01178827
View directory record Official record
Conditions
Overactive Bladder
Interventions
trospium chloride, oxybutynin IR, oxybutynin IR placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Results available

Oxybutynin Chloride in Managing Hot Flashes

NCT02961790
View directory record Official record
Conditions
Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes, Lobular Breast Carcinoma In Situ, No Evidence of Disease
Interventions
Oxybutynin Chloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Peoria, Illinois • Urbana, Illinois • Cedar Rapids, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Not applicable Interventional Results available

Enhancing Conservative Treatment for Urge Incontinence

NCT00223821
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Oxybutynin chloride, extended-release, individually-titrated, Behavior Training
Drug · Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
19 Years and older · Female only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 2 Interventional Results available

A Novel Pharmacological Therapy for Obstructive Sleep Apnea

NCT03919955
View directory record Official record
Conditions
Sleep Apnea
Interventions
Atomoxetine, Oxybutynin, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 2 Interventional

Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over

NCT00170768
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Darifenacin, Oxybutynin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
60 Years and older
Enrollment
150 participants
Timeline
2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 23, 2008 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 2 Interventional Results available

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

NCT01370811
View directory record Official record
Conditions
Sialorrhoea
Interventions
oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, oxybutynin and clonidine oral solution treatment C, oxybutynin and clonidine oral solution treatment D
Drug
Lead sponsor
Orient Pharma Co., Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bingham Farms, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 2, 2026, 4:07 AM EDT
Not listed Phase 2 Interventional

Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury

NCT03187795
View directory record Official record
Conditions
Spinal Cord Injuries, Urinary Bladder, Neurogenic
Interventions
Oxybutynin Chloride IR, Mirabegron
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers

NCT00752141
View directory record Official record
Conditions
Healthy Volunteers
Interventions
oxybutynin chloride immediate-release, oxybutynin chloride topical gel, placebo
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
60 Years to 79 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
6
States / cities
Tucson, Arizona • National City, California • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2011 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg

NCT00649727
View directory record Official record
Conditions
Healthy
Interventions
Oxybutynin Chloride ER Tablets 10 mg, Ditropan XL® Tablets 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults

NCT02633371
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Oxybutynin 3% gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 25 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 2, 2026, 4:07 AM EDT
Active, not recruiting Phase 2 Interventional

Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome

NCT05933603
View directory record Official record
Conditions
Obstructive Sleep Apnea, Down Syndrome
Interventions
Atomoxetine and Oxybutynin (ato-oxy)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
6 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy

NCT01829425
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
Anticholinergic medications, Hypnotherapy
Drug · Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg

NCT00649129
View directory record Official record
Conditions
Healthy
Interventions
Oxybutynin Chloride ER Tablets 10 mg, Ditropan XL® Tablets 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder

NCT00501267
View directory record Official record
Conditions
Overactive Bladder
Interventions
solabegron and oxybutynin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 4 Interventional Results available

Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

NCT04090190
View directory record Official record
Conditions
Urinary Incontinence, Urgency Urinary
Interventions
Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 2, 2026, 4:07 AM EDT
Active, not recruiting Not applicable Interventional

Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure

NCT05100017
View directory record Official record
Conditions
Kidney Calculi, Kidney Diseases, Nephrolithiasis, Urolithiasis, Ureteral Diseases, Ureteral Calculi
Interventions
Methocarbamol, Oxybutynin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

NCT00350636
View directory record Official record
Conditions
Overactive Bladder
Interventions
Oxybutynin topical gel, Placebo topical gel
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Homewood, Alabama • Mobile, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated May 10, 2010 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 3 Interventional

Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy

NCT03050827
View directory record Official record
Conditions
Diabetic; Neuropathic, Polyneuropathy (Manifestation)
Interventions
3% oxybutynin, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 2, 2026, 4:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg

NCT00649272
View directory record Official record
Conditions
Healthy
Interventions
Oxybutynin Chloride Extended-Release Tablets, 15 mg, Ditropan XL® Extended-release tablets, 15 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 2, 2026, 4:07 AM EDT